Radiopharmaceuticals: On-Going Research for Better Diagnosis, Therapy, Environmental, and Pharmaceutical Applications by Badria, Farid A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books








Research for Better Diagnosis, 




Radiopharmaceutical material is a pharmaceutical product or drug that 
may exert spontaneous degradation of unstable nuclei with nuclear particles or 
photons emission. Radiopharmaceuticals may be used in research, diagnosis, 
therapy, and environmental purposes. Moreover, radiopharmaceuticals act as 
radioactive tracers among patients via gamma-ray emissions. Therefore, the 
uses of radiopharmaceuticals as diagnostic agents may be given to patients 
to examine any biochemical, molecular biology, physiological, or anatomical 
abnormalities. Therapeutic radiopharmaceutical may be administered inter-
nally for therapeutic purposes via selective effect on certain abnormal cells 
or organs. The best known example for therapeutic radiopharmaceuticala is 
iodide131 for thyroid ablation in among patients with hyperthyroid. A third class 
of radiopharmaceutical is drug labeling which mainly used in research by using 
small amount of radioactive substances not for diagnostic purposes, but to 
investigate the metabolism, bio-distribution, pharmakodynamic, and phar-
makokinetic of certain drugs in a nonradioactive form. This chapter focuses 
mainly on basic fundamentals of radiopharmaceutical chemistry, prepara-
tion, environmental, pharmaceutical, diagnostic, therapeutic, and research 
applications.
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1. Introduction
Radiopharmaceuticals were first defined by the Federal Register of the USA as 
radioactive agents- potassium (40K) and carbon (14C) based natural compounds- or 
biological products contain unstable nuclei which may degrade spontaneously and 
emit photons or nuclear particles. These drugs might be prepared using nuclide 
generator or nonradioactive reagent [1].
Radiopharmaceuticals are categorized into 4 main classes: research, diagnostic, 
environmental and therapeutic pharmaceuticals as presented in Figure 1. Research 
radiopharmaceuticals are administrated to track metabolic reactions and kinetics 
including bio-distribution, bioavailability, pharmacokinetic, and pharmakody-
namic of a drug that is intended to be used later as nonradioactive form [1].
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Diagnostic radiopharmaceuticals Known as radioactive drugs/ompoundsc which 
used tracers for many diseases. Using gamma-ray emissions from radiopharma-
ceuticals drugs would help on broadcasting their positions inside the body. The 
concentrations of the radioactive materials could be deduced by observing these 
broadcasts in several organs. Images of different organs with low-resolution could 
be obtained using the signals [2].
The pharmacodynamics -the metabolism of the drug inside the body- and the 
kinetics could be studies by monitoring these broadcasts in a time-dependent 
manner. The device of monitoring is a collimated external gamma-ray detec-
tor. Therefore, in diagnosis purposes the radioactive materials are used to 
detect any sort of molecular, biochemical, physiological, and even anatomical 
abnormalities.
However, the diagnostic radioactive materials are not limited to gamma 
emitters types which allow their in-situ determination with noninvasive 
external radiation detectors. There are other types of radiopharmaceuticals 
that made of tritium, phosphorus 32, or carbon 14. Remarkably, these isotopes 
do not emit the same type of rays- gamma rays- therefore, it is impractical to 
monitor and examine their situation inside the body by external detectors. 
However, this type of isotypes could be applied in tracer diagnosis by analysis 
of samples. For instance, the administration of 14C to glucose and monitor-
ing the elimination of CO2 (
14C) in the breathing as metabolic end-product 
and used as indication for the assimilation of the compound, its metabolism 
throughout the body.
There are many variant body samples and fluids could be considered as well such 
as urine, blood, and biopsies samples in specific conditions.
Therapeutic radiopharmaceuticals are radioactive substance which could help 
in delivering the radiation entirely of body tissues by administration to radioac-
tive substances such as iodide I3I for thyroid removal in hyperthyroidism patients. 
The thyroid organ is irradiated entirely by radioactive iodine. Other different 
radiopharmaceutical materials could be used in treatment of cancer and known as 
radiotherapy [1].
Figure 1. 
Radiopharmaceutical applications in diagnosis, therapeutic, monitoring environment, and new trends in 
research.
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2. History of Radiopharmacy
Although training on the use and management of labeled compounds is pro-
vided in various institutions, the demand for pharmacists who specialize in radio-
labeled drugs has been determined, and radiopharmaceuticals have become the 
first specialty in the late 1960 in Pharmacy school at the U. of Southern California 
(USC), USA. The short-term research courses (usually 30 days for non-graduate 
students) and the radiopharmaceutical technician training program conducted 
from 1969 to 1986 enabled 201 pharmacists and other personnel to obtain a master’s 
degree in radiopharmaceuticals, and 15 of them obtained technology Certificate, 
and more than 500 people have participated and provide such expert training 
elsewhere and completed its plan in 1986 [3].
Clinical needs can be in image performances which may have a vital role either in 
staging or prognosis of the disease. Long ago, several programs that are educational 
and anxious with radiopharmaceutical analysis have not addressed this question. 
The program is frequently specialize in labeling a particular compound and on 
its application without any thoughts for its potential application in future. Even 
once a specific biological target is being targeted, the question of whether or not it 
addresses a true clinical would like is usually not considered [4]. The usage of radio-
labeled organism antibodies for imaging a neoplasm is taken into account a decent 
example. On the last decades, a great deal of studies were on developing programs 
based on aforesaid materials and this terminated and resulted in radiopharma-
ceuticals that may image cancer effectively and thought of as highly sensitive and 
specific methodology for imaging comparable or superior to other techniques.
3. Obstacles in academic research in radiopharmaceutical field
Most important modifications in health care in west were in the 1990’s. At this 
time, many resources became unrestricted in conjunction with complete clinical 
freedom and open-ended budgets this led to high level of control for health-care 
requirements with limited budgets, established protocols, and internal markets. The 
development of drug has regulated as well. Radiopharmaceuticals considered as one 
of the regulators which regulate conventional drugs which in turn increase the costs 
for the development of these drugs.
The academic discoveries in commercial development of radiopharmaceuticals 
were limited due to limitation in radiopharmaceutical industry and many vicis-
situdes in the institutions carrying out development in this field.
National nuclear centers whole over the world faced a lot of obstacles such as 
being privatized or being overburdened to make commercial gains. Academic 
funding for scientific research has also been cut off for long periods at universities. 
The academic curiosity was one of many reasons for scientists to put radiopharma-
ceutical field in the scope of research. To gain success in this field, projects should 
be developed, more directed, productive, and focused than was required earlier. 
Particularly, developing the clinical application of the product must be taken in 
consideration combined with the overcoming the financial obstacles. Therefore, 
unique new radiopharmaceuticals must fulfill a clinical requirement [5].
4. Nuclear medicine: clinical uses
Many new therapies in clinical practice have other requirements, such as man-
aged care plans and expensive restrictions. This represents both an opportunity 
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and a challenge for new radiopharmaceuticals [6]. It is necessary to maintain a 
reputation for safety and efficacy, and to improve existing treatments for any new 
products. In such a restrictive environment, it will be difficult to find a place in the 
market for radioactive compounds of these new drugs in clinical practice. Another 
way to introduce new and expensive treatments is to determine the subset of 
patients most likely to benefit from that particular treatment. The unique advantage 
of medicine is that it has the ability to combine diagnostic and therapeutic radionu-
clides for the same purpose, and may remain unchanged. In the future, diagnostic 
and therapeutic radiopharmaceutical pairs will increasingly be used to perform this 
function [6]. At the scientific level, radiopharmaceutical research has undergone a 
process of substitution in recent years. This review of compounds which describes 
certain aspects of current radiopharmaceutical research that have appeared in 
recently published literature or have become the subject of conference presenta-
tions [7]. Some of these issues are also the subject of more detailed review. However, 
this chapter deliberately excludes certain subject areas, especially not trying to 
cover developments in the field of positron emission tomography [7].
Radiopharmaceuticals are the cornerstone of nuclear medicine. Although there 
are many types of drugs that can study the structure and function of many essential 
organs, there is still a need for radiopharmaceutical substitution to study the subtle 
mechanisms of human body function. Under this trend, I5O, I8F and 123I appeared 
in the throttle body. With the emergence of such radionuclide-labeled drugs, 
especially the most widely used 99mTc, people are also doing their best to translate 
this success into daily clinical practice. β-labeled drugs can also be used for targeted 
radiotherapy of various malignant tumors. In addition to laboratories in industrial-
ized countries, some developing countries have also shown interest in these fields 
and participated in research projects [8].
Therapeutic radiopharmaceuticals have a critical effect on patient care spe-
cifically on medicine which have a promising role in the future. Many of latest 
therapies in clinical practice in need of different requirements like managed care 
programs, restrictions which are expensive. This symbolizes both a chance and a 
challenge for brand spanking new radiopharmaceuticals [6]. Efficacy and safety are 
among many others advantages to be added over the current treatments for any new 
product. Therefore, in such a restrictive environment there’ll be an issue for these 
new medicinal radio compounds to urge their place within the routine of clinical 
practice. Though, another route to abide with the new protocols is to define which 
group of patients may benefit from this special treatment. The strength of nuclear 
medicine is its capability to merge the uses of radionuclides in both diagnostic and 
therapeutic purposes for matching targets in diagnostic and therapeutic radiophar-
maceuticals [6].
This chapter describes, generally terms, some aspects of current radiophar-
maceutical research which have appeared within the recent published literature 
or are the topic of conference presentations [7]. Several of these topics are also 
the subject of more detailed reviews during this publication. However, some 
specialized areas of labor are deliberately excluded from this chapter, especially, 
no attempt is formed to hide developments within the field of Positron Emitting 
Tomography [7].
5. Radiopharmaceuticals and its bodily functions
Radiopharmaceuticals form the cornerstone of nuclear medicine. While the 
existing range of radiopharmaceuticals permits study of the structure and function 
of many important organs, there is a need for new radiopharmaceuticals that could 
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be used to explore more subtle mechanisms of bodily functions. Important progress 
has been achieved in this direction by the development of tracers labeled with 
cyclotron produced isotopes, including UC, 13 N, I5O, I8F and 123I. major efforts 
are also under way to translate this success into regular clinical practice by develop-
ing similar agents labeled with metallic radionuclides, particularly with the most 
widely used 99mTc. The agents labeled with beta emitting isotopes for potential use 
in the targeted radiotherapy of various malignancies is also being widely pursued. 
In addition to laboratories in advanced countries, several developing countries are 
also interested in these areas and have been participating in research programs 
organized by the IAEA. New advancement of Radiopharmaceuticals for therapy 
and Diagnosis will help speeding communication, and widespread knowledge for 
the better health of human being [8].
6. Current directions in radiopharmaceutical research
Nowadays, most of research in the area radiopharmaceutical is focusing on the 
tracers of receptor binding in biochemical reactions. The nature of these reactions 
may be Intra-extracellular in nature and may exhibit a good progress in tissue 
characterization using imaging technique in-vivo. Several of these agents are 
depending upon wide range of size; large MoAbs to tiny peptides (e.g. neuropep-
tide) which utilize bifunctional chelating agents to radiolabeling drugs/compounds. 
Radiopharmaceuticals of polypeptide may be in the brain whereas low molecular 
weight molecules retained high lipophilic characters to interact intercellular are 
highly needed (e.g. cell-surface receptors). Radiopharmaceutical chemists are fac-
ing many challenges to synthesis these compounds via one of two methods; namely 
integrated method or pendant method to utilize technetium coordination with 
interest on technetium (v) cores. Malignancy, neurology, inflammation, neurol-
ogy, and infectious diseases are among many other health disorders which are in 
dire need of cytotoxic radionuclides in the area of radioimmunotherapy. This may 
prompt researchers to focus their research and the newly developed radiopharma-
ceuticals toward specific clinical and biological targets [9].
7. Therapeutic applications
Emerging MoAbs associated with radionuclide(s) to target selective Tumors 
(antigens) may considered as an early research took place using iodine radionu-
clides in cancer. Moreover, some of these drugs/compounds are targeting the outer 
surface of cells, others may interact with the inner surface of the targeted cells. 
There are many examples for applications of different radiopharmaceutical in 
diverse therapeutic applications, e.g. nucleosides and their analogues in modula-
tion of both cell proliferation as well as mRNA transcription. Besides imaging of 
cell proliferation and mRNA transcription, a good advancement had been made to 
articulate a sort of tracers for imaging cell hypoxia. Interestingly, the progress in 
radiolabeled agents may exhibit remarkable benefits for speculating the resulted 
outcomes of tumors to radiotherapy beam which is greatly affected by the potential 
oxygen of the cell as in cardiac hypoxia. Discovery and search for new radiol-
pharmaceutical with new therapeutic applications revealed by chance non-nitro-
imidazole technetium-labeled molecule during a research program at Amersham 
International which is also trapped by reduction in hypoxic cells and this new agent 
is currently in the final stage of drug approval.. Several therapy applications are 
summarized in the next section [7].
Radiopharmaceuticals
6
7.1 Inflammation and infection
This area has provided a rich field for radiopharmaceutical research in last few 
years. Many of the newly developed radiopharmaceuticals products are derived 
from peptides, antibodies, cytokines, and polypeptides and very much similar to 
the ones which have been used in cancer [7].
The capability to image the indirect or direct inflammatory response to the 
infection is the key for clinical management with high selectivity, e.g. Antibiotic 
complex of Technetium (Ciprofloxacin = Tcinfecton “Tc”) [8]. Tc is good for 
labeling leucocytes to hammer Tc-leucocytes to place of infection. Several other 
examples, Tc-HMPAO, Tc-ECD, Tc-citrate, and Tc-glutathione etc. All of these Tcs 
proved to be concentrated in some tumor and/or inflammatory sites. Moreover, 
other complexes for imaging inflammation, e.g. human immunoglobulin Gb and 
99Tcm “HIgG-99Tcm” is an interesting serendipity drug developed from the reduc-
tion of disulphides (-S-S-) under very mild conditions to produce free –SH groups. 
The efficacy of the formed labeled chemotactic complexes act as substrate(s) for 
imaging infection via binding to receptors whereas WBC (leucocytes) are in high 
concentration at the location of infection [8, 10].
7.1.1 Tcm-Ciprofloxacin
HPLC analysis showed that the efficacy of the radiolabeled Tcm-Ciprofloxacin 
is over 95%. Meanwhile, In vivo bioavailability studies using mice showed that 
“Tcm-CIP is quickly bioavailable and distributed upon intravenous administration 
with a major renal clearance. In the infection inflammatory model on mice induced 
by turpentine oil, S. aureus, and E. coli, the radiopharmaceutical preparation was 
successful in localization of bacteria in the inflamed site [11].
7.2 Neurology and psychiatry
Molecular biology plays a crucial role in identifying many receptors and sub-
type receptors for neurotransmitters. Subsequently, this encourages radiopharma-
ceutical industry to conduct neuroreceptors brain imaging as is one of the major 
application of the radiopharmaceutical research [7].
7.3 Renal tubular function agents
A true replacement to hippuran-123I has been a challenging task in the devel-
opment of technetium complexes, as no Tc compound is completely extracted 
and secreted into urine. It has, however, been possible to develop compounds 
which are handled by the renal tubules and actively secreted into urine. Structural 
feature requirements for recognition by renal tubules and for delivery by serum 
protein bound transport propounded way back by Despopoulos, [-C(=O)-NH-
CH2-COOH], have been sought in the technetium complexes to achieve some 
degree of success. For most clinical purposes, a renogram agent based on renal 
tubular handling would be very much more useful, apart from being superior to 
purely GFR based agent such as 99Tcm -DTP A, and hence the intense research 
efforts. Tc-MAG3 complex contains the structure referred to above, while Tc-EC 
has a structural mimic, 3 oxygen atoms at 3–4 A0 to one another in Tc(=O)-NH-
CH2-COOH, cf. -C(=O)-NH-CH2-COOH [9]. Both Tc-MAG3 and Tc-EC show 
less excretion than hippuran, but Tc-EC has relatively superior features. The 
room temperature formulation recipe of Tc-EC is another practical advantage. 
The early apprehensions of differences in the purity of kit formulated and 
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chromatographically purified product were removed with refinements in kit 
formulation procedures. However, due to inherent nature of possible trace impuri-
ties in MAGS synthesis as well as different types of TcMAG3 complexes feasible, 
interference from hepatobiliary involvement during renography studies has not 
been ruled out. One study is in fact devoted to the anomalies in Tc-MAG3 behavior, 
Modifications to MAG3 ligands to overcome the drawbacks have been sought, 
replacing glycine by another amino acid, introduction of chiral center to influence 
the stereochemical role etc.; some superior results have been achieved, like 99Tcm 
-D-MAGAG. Tc-L, L-EC requires to be prepared at highly alkaline pH of 11–12 and 
it is consequently difficult to present in a reliable single component lyophilized 
kit form, though a commercial kit has been cited in literature. Detailed stringent 
protocol for kit formulation has been suggested. A multi-component kit recipe 
would be generally necessary, but advantage of ease of transchelation (using 
GHA) based kit has also been reported. As discussed earlier, the development of 
Tc-EC for renal tubular function, is an outcome based on the excretory pattern of 
Tc-ECD and the study of its metabolite(s) [12]. The attempts to utilize cysteine, 
cystine and analogues for complexing technetium for obtaining renal agents had 
shown mixed findings, but the same group from India has recently demonstrated 
a new product for renal tubular function imaging. 99Tcm complex of dimethyl 
ester of DTPA denoted as Tc-DMDTPA, has shown promising results including in 
human volunteers. Analogous to Tc-DTPA, the Tc-DMDTPA complex is anionic, 
but has predictably less (−50%) electrophoretic mobility. Ease of reliable, stable, 
single component lyophilized kit formulation, room temperature preparation 
of Tc-DMDTPA in high yield, purity and stability and similarity in biological 
behavior to hippuran- l j lI and Tc-MAG3 in both normal and probenecid (renal 
tubular transport inhibitor) treated mice are the salient advantages reported. A 
cationic pathway renal tubular agent has also been reported from UK involving the 
complex of 1,2-diaminocyclohexane (DACH). The product, [Tc(V)02(DACH)2]”, 
is formulated using stannous tartrate reduction of pertechnetate and has shown 
utility for eliciting renal tubular function, when anionic pathway is not freely 
accessible due to high concentrations of circulating anions, like during chemo-
therapy [9, 12].
8. Research and Development
8.1 Milestones and concepts in the evolution of new products
In the genesis of the growth of 99Tcm compounds, the introduction of DTPA 
chelate of technetium, use of stannous tin for reduction of Tc (VTT) in pertechne-
tate and lyophilization of premixed stannous tin - ligand formulation would merit 
the first mention despite the passage of time. Suitable variation(s) in the functional 
groups on the ligand backbone to influence the pharmaco-kinetic behavior of the 
resultant technetium complexes, while retaining the same chelating environment 
for technetium, was a major development. This eventually led to introduction of 
the most preferred hepatobiliary tracer, 99Tcm-mebrofenin [2]. Such systematic 
investigations of structure - activity distribution relation (SADR) provided a 
fresh approach for the development of many other new products. The concept of 
bifunctional nature of ligands was also propounded after this work, for in LID As, 
IDA groups participate in complexing technetium, while the phenylcarbamoyl 
moiety bestows some of the required biological features. Although in the present 
sense of the term BCA, this may not be strictly correct, the way was paved for a new 




99Tcm based receptor radiopharmaceuticals are not yet a clinical reality. The only 
successful case is that of 99Tcm - neogalactosyl glycoalbumin (NGA) for a bound 
receptor named hepatocyte binding protein (HBP) receptor, that binds galactose end 
glyco proteins. Tc-NGA would be useful for staging certain liver diseases (since HBP 
is implicated in liver malignancy) and for monitoring response to therapy [13]. The 
concept of BCA to attach receptor specific molecules with 99Tcm has been exten-
sively investigated, but with limited success. Arduous chemical studies followed 
by receptor binding experiments have revealed poor specificity in most cases, like 
[Tc(V)O(DADS)-Progestin],[Tc(ra)(CO)(diethyldithiocarbamato-Spiperone)3], 
[Tc^-BATO-QNB] & [Tc(V)O(DADS)-QNB]. It appears that in all cases the com-
plexation with technetium severely alters the bioactivity and precludes receptor 
binding. Attempts to overcome steric effects by increasing the distance between the 
essential functional groups have not been much successful. The important aspects to 
be reckoned with are molecular weight & size, lipophilicity changes, stereochemical 
effects and non-specific binding; two approaches called tridentate-monodentate 
(3 + 1) scheme (the former for facile chelation with Tc and the latter for presenting 
the receptor avid moiety) and pendant scheme have been pursued [13]. The novel 
concept of molecular mimics, i.e. Tc-chelate simulating a regular ring structure in 
a native receptor binding molecule, especially in a steroid (e.g. progesterone)/drug 
(e.g. morphine), is being pursued to target receptor sites for imaging using 99Tcm. 
Radiolabeled peptides have been recognized as the most likely successful candidates 
for imaging receptors (covered in another article in this Volume), based on the prom-
ising experience with mini labeled octreotide. The earlier stated problems in disguis-
ing and presenting technetium to the receptors persist, but scope for optimism is 
seen in this approach. In view of the importance of receptor imaging capability in 
health and disease, research efforts are continuing in more than one way [13, 14].
8.3 Computational chemistry of metal-based radiopharmaceuticals
Calculation of radiopharmaceutical doses is a very crucial process and consid-
ered one of the main task of radiopharmacist as illustrated later. It is noteworthy to 
mention that there is the method of prescription calculation is completely different 
from conventional organic drugs. The most common method of calculation or 
computational chemistry of metal-based radiopharmaceuticals [14]. Other factors 
must be considered and may have role in pharmacokinetic and biodistribution, e.g. 
molecule geometry, dipole moments, ionic charge [15].
8.4 Bioevaluation (biological assessment)
Eventhough methods of diagnosis and therapy are very important for both 
patients and physicians but bioevaluation or biological assessment protocol(s) are 
highly recommended [16–20]. The studies proved that some chelating agents (e.g. 
EDTA and DPTA) may chelate radionuclides to provide good images especially in 
cases of advanced cancer. For early diagnosis, Re-186(V) and Re-188(V)-DMSA are 
among drugs which will help in both diagnosis and monitoring cancer with good 
bio-distribution and pharmacokinetics properties [21]. This will enable specialist to 
understand if the radiopharmaceutical reached the appropriate location or site(s) 
(tumor for example). This also may enhance the delivery and improver the efficacy 
of drug [21]. Interestingly, measuring all three tumor space could be examined in 
vivo using drugs labeled with 95 mPt [22]. This protocol is valuable for cytotoxic 
drugs via the first pass phenomenon, e.g. cisplatin and 5-FU. However, other drugs 
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that control tumor via a slow diffusion mechanism will behave differently. The use 
of radiopharmaceutical in meager quantity may help in calculating the number of 
locations/sites needed to attain the optimal delivery and bio-distribution to reach 
the best therapeutic activity [23–27].
Coupled with the ease of antibody production, these facts make 125 I-labeled 
immunoassays an ideal choice for many research activities [28, 29], especially in the 
medical field where radioisotopes are In short, even a cursory examination of the 
public health statistics of different countries on all continents shows the need for a 
simple, economic, and reliable analytical with this in mind, it is expected that [30].
8.5 Current status of radioactive signal immunoassays
The future development of radiolabeled immunoassays use reagents containing 
radioisotopes as indicators to monitor the distribution of free and bound antigens 
or free antibodies The distribution of free antibodies (free Immune radiological 
reagent analysis. (IRMA) [28, 29, 31–33].
8.6  Development of a simple immunofluorescence test method that uses 
AVIDIN to connect with general polystyrene spheres
Immunoradioassay (IRA) based on using beads of polystyrene as solid 
phase conjugated to avidin [34]. The commercially MoAbs is bio-tinylated with 
N-hydroxysuccinimide ester of biotin aminocaproate, and the detection Ab is I125.
A simple assay composed mainly of two steps;, mixing 2 labeled Abs with either 
sample or positive control [35]. This method has been used for hormonal analysis; 
Lutinizing hormones (LH), Follicle Stimulating Hormones (FSH), and prolactin 
[36]. For example, theaccuracy in analysis of prolactin is 8 (μU/ml (0.3 ng/ml), FSH 
is 1 mlU/ml, and LH is 0.9 mlU/ml [37].
8.7 Magnetic particle separation technique
There are 5 classes of magnetic particles(MP) (with/or without –CHO, NH2-, 
and COOh groups) were used to conjugate the 1st or 2nd antibody(Ab) using three 
methods; immmunoaffinity, adsorption, and chemical coupling to form 4 dif-
ferent MPAbs [38]. The 2nd immobilized Ab on polyacrolein MPs through -CHO 
and also the 1st Abs immobilized on -COO polystyrene MPs through -COOH to 
use in RIAs and/or IRMAs [39]. Commercial MPS were immobilized on NH2- for 
“Streptavidin” to separating polymerase chain reaction product quantitatively for 
CMV (Cytomegalovirus) [40, 41].
There are over forty eight cyclotrons and forty two reactors to provide radioiso-
topesfor biomedical applications [42, 43].
Nuclear reactors have played a main role in production of radioisotopes required 
for medical, industrial, agricultural purposes, education within the nuclear sci-
ences and research. Millions of people worldwide have benefited from the 99Mo 
- > 99mTc generator for diagnostic imaging, and 131I for the treatment of cancer. 
Advances in accelerator and medical imaging technology are driving the demand 
for radioisotopes and radiopharmaceuticals required by nuclear medicine [44]. 
Conditions like public perception arising from concern for the environment either 
from radiation accidents or future storage of nuclear waste, additionally because 
the operating and replacement costs for aging reactors are factors influencing the 
prospects of future availability of radioisotopes. This may well be often reflected 
in recent decisions taken to initiate the de-commissioning of some research TRIGA 
reactor(s) that were installed in hospitals during the 1960’s [45].
Radiopharmaceuticals
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8.8 Design of radiopharmaceuticals and gene transfer therapy
Gene transfer therapy among cancer patients require monitoring emission for 
better management during treatment as presented in Figure 2 [46–49]. The first 
clinical experience employing gene therapy was gained in 1989. leukocytes were 
transduced with heterologous DNA to look at the biological in vivo properties of 
tumor-infiltrating lymphocytes, and thereby optimizing antitumour imrnuno-
therapy strategies [50]. There are numerous approaches were undertaken to use 
powerful strategy of therapeutic gene transfer to the majority varieties of human 
diseases [51].
8.9 Radiopharmaceuticals for diagnosis and tumor therapy
For effective imaging in diagnosis and tumor therapy [52], three enzymes 
-which are not commonly expressed by normal/non-infected cells- encoded by viral 
gene are required [53]:
1. Nucleoside kinase: This enzyme can convert selectively the unnatural nucleo-
sides to nucleotides in gene-transfected cells or in virus-infected cells does not 
act on normal cells as in case of thymidine kinase(TK), e.g. Herpes simplex-I 
(HSV-I TK) [54].
2. Tyrosinase: These enzyme can convert tyrosine amino acid to L-dopa, dopa-
mine, dopaquinone and melanin via either neurotransmitter or pigmentation 
pathways, e.g. melanomas
3. Reductases: These enzyme are active mainly within the liver in hypoxic tissues. 
The process of bioreduction of active compounds may enhance the sensitivity 
of the hypoxic cells to the radiolabeled compound [55].
Figure 2. 
Selective prodrug gene therapy.
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9. Relation between Physcian in nuclear medicine and Radiopharmacist
Nuclear Pharmacy or Radiopharmacy is currently a very well recognized 
pharmaceutical specialty and a sort of cooperation is highly recommended to build 
a strong and clear relation between Physcian in nuclear medicine and radiopharma-
cist. The concept of this relation is presented in Figure 3. In 1970, radiopharmacy 
speciality was recognized by the American Board of Pharmaceutical specialties. 
Nowdays, radiopharmacy has implemented in many health care systems with 
official credential certificate. Meanwhile, each country has its own regulatory 
radiopharmacy products [56].
10. Conclusion
As the search continues for new products and newer areas of applications, 12jI 
compounds would provide the vital bridge between truly biological PET tracers 
based on nC/18F labeled compounds and the much more easily accessible SPECT 
tracers based on “Tcm and inIn products, thereby rendering a transition from 
PET to SPECT, that is from medical research to clinical utility, a reality. products 
would provide a fine complement to “Tcm compounds, especially for imaging 
process(es) involving slower kinetics of tracer and in the cases where conjugation 
of In-BCA with the bio-active substrate causes less alterations of the biological 
activity. Though the question “After 99Tcm, what next?” is posed time and again, 
Figure 3. 
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the well-known attractive advantages of 99Tcm are not likely to be matched by 
any other tracer in the foreseeable future and consequently the impetus to develop 
99Tcra based radiopharmaceuticals will continue. It could be safely predicted that 
the future of radiopharmaceuticals and in turn, clinical nuclear medicine, will 
continue to be dominated by “Tcm products, as has been the case in the past.
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